Aptahem AB (XSAT:APTA) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Aptahem AB Days Payable?

Aptahem AB's average Accounts Payable for the three months ended in Mar. 2024 was kr0.91 Mil. Aptahem AB's Cost of Goods Sold for the three months ended in Mar. 2024 was kr-0.61 Mil.

The historical rank and industry rank for Aptahem AB's Days Payable or its related term are showing as below:

XSAT:APTA's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.28
* Ranked among companies with meaningful Days Payable only.

Aptahem AB's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same

Aptahem AB Days Payable Historical Data

The historical data trend for Aptahem AB's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptahem AB Days Payable Chart

Aptahem AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Aptahem AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Aptahem AB's Days Payable

For the Biotechnology subindustry, Aptahem AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptahem AB's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptahem AB's Days Payable distribution charts can be found below:

* The bar in red indicates where Aptahem AB's Days Payable falls into.

Aptahem AB Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Aptahem AB's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (3.697	+	0.966)	/	2 )	/	-2.631	*	365
=	2.3315					/	-2.631	*	365
=	N/A

Aptahem AB's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (0.966	+	0.856)	/	2 )	/	-0.609	*	365 / 4
=	0.911					/	-0.609	*	365 / 4
=	N/A

Aptahem AB Days Payable Related Terms

Thank you for viewing the detailed overview of Aptahem AB's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptahem AB (XSAT:APTA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptahem AB (XSAT:APTA) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Norra Vallgatan 58, Malmo, SWE, 211 22

Website

http://www.aptahem.com

Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.

Aptahem AB (XSAT:APTA) Headlines

No Headlines